Psychoses
17
0
0
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
29%
5 trials in Phase 3/4
0%
0 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (17)
Epileptic Psychoses and Their Link With Ictal Emotions and Consciousness
Adapting a Socio-cognitive Intervention to Early Psychosis Services
Patient-controlled Admissions in Inpatient Mental Health Services
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
Pharmacy Interventions to Improve Chronic Disease Medication Refill
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
Access, Detection and Psychological Treatments
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
Brain Cell Injury in Patients With A First Episode of Psychosis
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug